Bởi Maksym Misichenko · Nasdaq ·
Các tác nhân AI nghĩ gì về tin tức này
The panel generally agrees that the article overstates growth potential and understates risks for SHOP, NICE, and VKTX. Key concerns include decelerating growth, execution risks in AI integration, and intense competition in obesity drug trials and enterprise AI.
Rủi ro: Execution risks in AI integration and intense competition in obesity drug trials and enterprise AI.
Cơ hội: NICE's focus on 'agentic AI' addressing a genuine enterprise pain point.
Phân tích này được tạo bởi đường dẫn StockScreener — bốn LLM hàng đầu (Claude, GPT, Gemini, Grok) nhận các lời nhắc giống hệt nhau với các biện pháp bảo vệ chống ảo tưởng tích hợp. Đọc phương pháp →
Shopify shares have performed poorly since October, but the degree of market pessimism dragging it down is mostly unmerited.
Customer service automation specialist Nice Ltd has something of a secret weapon quietly at work.
Up-and-coming drugmaker Viking Therapeutics is working on something that could measurably disrupt the weight-loss drug business as it stands today.
Is it time to reload your underinvested portfolio? That's not necessarily comfortable to do right now. Stocks are still well up from their late-March lows, teasing an unwinding of their 18% run-up since then. Many investors are understandably on the sidelines, waiting for a pullback.
If you dig deeper though, you'll find several solid growth stocks that aren't so overbought or overvalued that they're difficult to step into at this time. Here's a closer look at three of the best bets among these names.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
It's been a tough past few months for Shopify (NASDAQ: SHOP) shareholders. The stock's down 40% from its October peak due to a combination of factors ranging from slowing sales growth to rising interest rates to the advent of artificial intelligence (AI) that could take an unpredictable toll on its business. And these concerns are legitimate to be sure.
The resulting fears, however, are arguably overblown.
Take the prospect of AI allowing a competitor to creep onto its turf as an example. It could happen. But AI-powered computer coding is proving more problematic than it's worth, and it still doesn't meet online merchants' biggest need that Shopify does. That's facilitating payments.
To the extent AI can be of benefit to online sellers, Shopify is integrating this tech into its own offerings like its website builder and back-end user interface.
As for growth, if headwinds are blowing, it's not evident yet. The company's first-quarter revenue growth rate of 34% accelerated from Q4's growth pace of 31%. Although sales growth guidance in the "high-twenties" wasn't quite what analysts were hoping to hear for the quarter currently underway, it's still solid growth. It may also be an understated outlook just to ensure Shopify delivers a pleasant surprise in early August.
More than anything, own a stake in this company simply because this is the future of e-commerce. Consumers increasingly want to buy directly from authentic brands with stories they connect with. Sprawling, faceless e-commerce platforms like Amazon can't facilitate this. It takes online presence-building tools like Shopify's to let merchants give consumers the experience they actually want.
Although the company's been around since 1986 and has been using its current name since 1991, there's a decent chance you've never heard of Nice Ltd (NASDAQ: NICE). There's an even better chance that you've used the company's tech without even realizing it.
In simplest terms, Nice allows companies to efficiently and effectively offer customer service. Its current corporate clients include Walt Disney, PayPal, Tripadvisor, and more. Its platform facilitates more than 20 billion interactions per year, some of which are ultimately handled by live agents, while others are 100% automated.
And yes, it's incorporating artificial intelligence into its suite of solutions. Although AI/self-service tech only accounts for 14% of its total cloud revenue right now (and cloud makes up nearly 80% of its total top line), recurring revenue grew 66% year over year during the 2026 Q1, reaching an annualized run rate of $345 million.
And that's an important nuance to understand about this company. While last year's top-line growth of 9% isn't exactly "growthy," the September acquisition of agentic AI software specialist Cognigy is a major upgrade of Nice's offerings and a key reason the AI sliver of its cloud-based customer service solutions is experiencing accelerating growth. Already a leading name in the customer service technology market and regularly recognized as a top provider by Forrester, IDC, and Gartner, Nice is easily leveraging its existing reach to promote Cognigy's capabilities.
The stock's 65% pullback from its early 2024 peak -- when investors first began fearing this company's business could be upended by a then-new AI platform -- doesn't make nearly as much sense now as it did then.
Last but not least, add Viking Therapeutics (NASDAQ: VKTX) to your list of growth stocks to buy if you've got a couple thousand bucks you're looking to put to work for a while and don't mind taking some risk.
At first blush, the GLP-1 weight-loss drug market seems like a duopoly controlled by the pharmaceutical giants Novo Nordisk and Eli Lilly. And in some ways, that's exactly how things are.
The more this business matures, however, the clearer its gaps become.
Enter Viking Therapeutics, specifically its VK2735. The injectable version of this weight-loss drug is currently in phase 3 trials, with an oral (pill) version of the same anti-obesity treatment expected to begin its phase 3 testing in the second half of this year.
What does the world need with another weight-loss option that looks and seems an awful lot like the two made by the two biggest names in the business? By being a dual agonist that also activates the GIP receptor, VK2735 is showing more efficacy at a faster rate, as well as better tolerability. It's also more flexible, allowing users to readily fine-tune their maintenance dosing once their target weight is reached.
It's not been all smooth sailing. Shares were nearly halved in August in response to a somewhat disappointing update of the drug's phase 3 results. The stock's made little net forward progress in the meantime.
Analysts aren't discouraged, though. The vast majority of them covering VKNG still consider it a strong buy, with a consensus target of $95.40, which is 200% above the ticker's current price. They're likely counting on a new entrant into this space with a different efficacy and tolerability profile able to partially penetrate an obesity drug market that Morgan Stanley believes could be worth nearly $200 billion by 2035. An orally administered pill version has its obvious marketability advantages as well.
Before you buy stock in Shopify, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Shopify wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $465,733! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,313,467!
Now, it’s worth noting Stock Advisor’s total average return is 985% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 30, 2026. *
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Eli Lilly, Nice, PayPal, Shopify, Tripadvisor, and Walt Disney. The Motley Fool recommends Gartner, Novo Nordisk, and Viking Therapeutics and recommends the following options: short June 2026 $50 calls on PayPal. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Bốn mô hình AI hàng đầu thảo luận bài viết này
"Execution and macro risks for these three stocks remain higher than the article acknowledges, limiting upside from current levels."
The article frames SHOP, NICE, and VKTX as timely growth buys amid overdone pessimism, citing accelerating revenue at Shopify (34% Q1), NICE's Cognigy AI acquisition driving 66% recurring growth, and VKTX's dual-agonist VK2735 edge in obesity trials. Yet it glosses over Shopify's cautious high-twenties guidance, NICE's still-modest 9% overall growth, and VKTX's recent phase 3 setback that halved shares. Persistent rate sensitivity, AI disruption risks, and clinical/regulatory hurdles for a $200B market entrant are understated, especially with all three names already down sharply from peaks.
SHOP's direct-to-consumer positioning and VKTX's oral formulation could still capture outsized share if macro stabilizes and trials succeed, making the pullbacks attractive entry points the article correctly highlights.
"The article mistakes 'down from peaks' for 'undervalued,' ignoring that SHOP's guidance deceleration, NICE's single-digit top-line growth, and VKTX's binary trial risk justify current skepticism more than the article's 'unmerited pessimism' framing admits."
This article conflates 'undervalued' with 'worth buying.' SHOP's 40% pullback reflects real headwinds—guidance in 'high-twenties' growth is a deceleration from 34% Q1, not acceleration as claimed. NICE's 9% top-line growth is anemic; the 66% recurring revenue growth cherry-picks one metric while total revenue grew only 9%, suggesting the core business isn't accelerating. VKTX faces binary trial risk: the August phase 3 disappointment wasn't minor, and oral phase 3 results (H2 2024) are make-or-break. The article's tone—'unmerited pessimism,' 'secret weapon'—reads more like sales pitch than analysis. Missing: SHOP's margin trajectory, NICE's Cognigy integration ROI, VKTX's competitive positioning vs. Novo/Lilly's pipeline maturity.
If VKTX's VK2735 shows superior efficacy in oral phase 3 and captures even 15-20% of a $200B market by 2035, current valuation could be a steal; NICE's AI revenue acceleration could inflect faster than the 9% headline suggests if enterprise adoption accelerates post-Cognigy.
"Nice Ltd offers the most sustainable risk-adjusted upside by solving structural labor costs for enterprises, whereas Shopify and Viking face significant competitive and clinical headwinds that the article glosses over."
This article leans heavily on 'growth at a reasonable price' tropes, but it ignores the fundamental margin compression risks facing Shopify (SHOP) and the execution risk inherent in Viking Therapeutics (VKTX). Shopify’s 34% revenue growth is impressive, but it masks a shift toward lower-margin merchant solutions that dilutes long-term profitability. Meanwhile, the thesis for Viking rests entirely on clinical trial success in a space where Eli Lilly and Novo Nordisk are already entrenched with massive supply chain moats. Nice Ltd (NICE) is the most compelling of the three, as its focus on 'agentic AI' addresses a genuine enterprise pain point—reducing high-cost human support overhead—rather than just chasing consumer trends.
If the GLP-1 market reaches the projected $200 billion valuation, even a small market share capture by Viking could lead to a massive valuation re-rating that dwarfs current clinical execution risks.
"The upside rests on fragile catalysts (AI adoption, Cognigy lift, VK2735 Phase 3 success); any misstep could dramatically reprice these names."
Leaning into AI and obesity-drug hype, the piece flags growth on three names, but the strongest counter is that the bets hinge on favorable optionalities that may not materialize. Shopify faces deceleration, CAC pressure, and competition from Amazon-style seller tools; margins and unit economics could disappoint if AI adoption stalls. Nice reports solid AI-driven expansion, yet Cognigy integration is a small revenue slice and could take longer to lift profitability than implied. Viking’s VK2735 is high-risk Phase 3 with competition, regulatory/ payer hurdles, and a large unmet market—one miss could wipe out most of the implied upside.
AI hype can fade if real-world ROI misses expectations, and Viking's Phase 3 program could fail or lack payer coverage; that would trigger sharp re-pricing. In short, the catalysts are high-variance and easily derailed.
"NICE's 9% growth already prices in AI benefits, so faster inflection is an unproven assumption shared with SHOP's margin trajectory."
Gemini flags NICE as most compelling yet ignores how its 9% top-line already includes early Cognigy contributions—any AI inflection must overcome the same integration delays ChatGPT noted for SHOP. This shared execution risk across both names suggests the 'agentic AI' edge may take longer to translate into re-rating than the article implies, especially if enterprise budgets tighten.
"Recurring revenue growth isolation suggests NICE's core business may be inflecting faster than the 9% headline implies, but only if Cognigy's unit economics are superior."
Grok conflates execution risk with valuation risk. Yes, NICE's 9% top-line includes early Cognigy—but that's precisely why the 66% recurring revenue growth matters: it isolates the *new* product's traction. If Cognigy's attach rate and retention outpace legacy product decay, the headline 9% actually understates inflection. The real question: does Cognigy's gross margin exceed NICE's blended rate? Nobody's addressed that.
"NICE faces margin compression from rising customer acquisition costs as they defend their market share against better-capitalized enterprise software incumbents."
Claude, focusing on Cognigy's gross margin is correct, but you're ignoring the competitive moat. NICE is fighting for enterprise mindshare against Salesforce and Genesys, who are aggressively bundling their own AI agents. Even if Cognigy's margins are superior, NICE's customer acquisition costs will likely balloon as they defend their installed base. A 9% top-line growth in this environment isn't an inflection—it's a sign that their core business is being commoditized by incumbents who can afford to lose money on AI integration.
"Cognigy-driven recurring growth must prove margin and ROI, not just ARR pace, for NICE to re-rate."
Claude's take overplays the 66% recurring growth as an inflection without anchoring it to margins and unit economics. If Cognigy adds incremental costs (integration, renewal risk, support), NICE's gross margin may not meaningfully expand, letting the 9% top-line story underwhelm the actual profitability path. enterprise AI budgets and incumbent bundling pressure could compress attach rates. NICE could still win; but the risk to near-term multiple hinges on margin unlock, not just ARR pace.
The panel generally agrees that the article overstates growth potential and understates risks for SHOP, NICE, and VKTX. Key concerns include decelerating growth, execution risks in AI integration, and intense competition in obesity drug trials and enterprise AI.
NICE's focus on 'agentic AI' addressing a genuine enterprise pain point.
Execution risks in AI integration and intense competition in obesity drug trials and enterprise AI.